Rosuvastatin for the treatment of hypercholesterolemia.

about

Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.Short-term memory loss associated with rosuvastatin.

P2860

Q37629758-C595AE01-F6C4-4A08-AE5F-CD7F3AB1EB76 Q51980745-B5DC86B6-2BE3-4C42-AA38-B5A5B093E184

P2860

Rosuvastatin for the treatment of hypercholesterolemia.

Item

http://www.wikidata.org/entity/Q36188328

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Rosuvastatin for the treatment of hypercholesterolemia.

@ast

Rosuvastatin for the treatment of hypercholesterolemia.

@en

type

Item

label

Rosuvastatin for the treatment of hypercholesterolemia.

@ast

Rosuvastatin for the treatment of hypercholesterolemia.

@en

prefLabel

Rosuvastatin for the treatment of hypercholesterolemia.

@ast

Rosuvastatin for the treatment of hypercholesterolemia.

@en

P1476

Rosuvastatin for the treatment of hypercholesterolemia.

@en

P2093

Jeannine R Skae

http://www.w3.org/2001/XMLSchema#string

Nicole S Culhane

http://www.w3.org/2001/XMLSchema#string

Shana L Lettieri

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

P304

990-1000

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.2005.25.7.990

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16006277

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia

Rosuvastatin for the treatment of hypercholesterolemia.

about

P2860

P2860

Rosuvastatin for the treatment of hypercholesterolemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921